Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile

Journal of Clinical Pathology

Volumn 51, Issue 11, 1998, Pages 818-824

  Ceccarelli, Claudio ^a   Santini, Donatella ^b,d   Chieco, Pasquale ^d   Taffurelli, Mario ^c   Gamberini, Michela ^a   Pileri, Stefano A ^b   Marrano, Domenico ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Secondo Serv Anat Istol P

^c Clinica Chirurgica I   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Breast cancer; Immunohistochemistry; pRb; Retinoblastoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; GENE PRODUCT; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ANTIBODY LABELING; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CELL CYCLE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETINOBLASTOMA; TUMOR SUPPRESSOR GENE;

EID: 0031741123     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.51.11.818     Document Type: Article

References (47)

1. Cordon-Cardo C. Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995;147:545-60.
2. Nevins JR. E2F: a link between the Rb tumor suppressor protein and the viral oncoproteins. Science 1992;258:424-9.
3. Musgrove EA, Hui R, Sweeney KJE, et al. Cyclins and breast cancer. J Mammary Gland Biol Neopl 1996;1:153-62.
4. Marx J. How the retinoblastoina gene may inhibit cell growth. Science 1991;252:1492.
5. Haas-Kogan DA, Kogan SC, Levi D, et al. Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 1995;14:461-72.
6. Martinez JC, Piris MA, Sanchez-Beato M, et al. Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with Ki-67 growth fraction. J Pathol 1993;169: 405-12.
7. Seki S, Kawakita N, Yanai A, et al. Expression of the retinoblastoma gene product in human hepatocellular carcinoma. Hum Pathol 1995;26:366-74.
8. Jares P, Campo E, Pinyol M, et al. Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol 1996;148:1591-600.
9. McIntosh GG, Anderson JJ, Milton I, et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 1995;11:885-91.
10. Cavenee WK, Dryja TP, Philips RA, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983;305:779-84.
11. Harbour JW, Lai S-L, Whang-Peng J, et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988;241:353-7.
12. Stratton MR, Williams S, Fisher C, et al. Structural alterations of the RB1 gene in human soft tissue tumours. Br J Cancer 1989;60:202-5.
13. Horowitz JM, Park S-H, Bogenmann E, et al. Point mutational inactivation of the retinoblastoma antioncogene. Science 1989;243:937-40.
14. Lee WH, Bookstein RE, Lee EYHP. Molecular biology of the human retinoblastoma gene. In: Klein G, ed. Tumour suppressor genes. New York: Marcel Dekker, 1990:160-99.
15. Liu Y, Heyman M, Wang Y, et al. Molecular analysis of the retinoblastoma gene in primary ovarian cancer cells. Int J Cancer 1994;58:663-7.
16. T'Ang A, Varley JM, Chakraborty S, et al. Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 1988;242:263-6.
17. Lee EY, To H, Shew J-Y, et al. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 1988;241:218-21.
18. Varley JM, Armour J, Swallow JE, et al. The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumors. Oncogene 1989;4:725-9.
19. Trudel M, Mulligan L, Cavenee W, et al. Retinoblastoma and p53 gene product expression in breast carcinoma: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol 1992;23:1388-94.
20. Borg A, Zhang Q-X, Alm P, et al. The retinoblastoma gene in breast cancer; allele loss is not correlated with loss of gene protein expression. Cancer Res 1992;52:2991-4.
21. Benedict WF, Xu HJ, Hu SX, et al. Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest 1990;85:988-93.
22. Dodson MK, Cliby WA, Xu H-J, et al. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RBG locus. Cancer Res 1994;54:610-13.
23. Dei Tos AP, Maestro R, Doglioni C, et al. Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol 1996;148:1037-45.
24. Sawan A, Randall B, Angus B, et al. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol 1992;168;23-8.
25. Bianchi S, Calzolari A, Giannelli E, et al. Expression of retinoblastoma protein in human breast cancer: an immunohistochemical study. Pathologica 1995;86:146-9.
26. Pietilainen T, Lipponen P, Aaltomaa S, et al. Expression of retinoblastoma gene protien (Rb) in breast cancer as related to established prognostic factors and survival. Eur J Cancer 1995;31A:329-33.
27. Anderson JJ, Tinaikos DG, McIntosh GG, et al. Retinoblastoma protein in human breast carcinoma: immunohistochemical study using a new monoclonal antibody effective on routinely processed tissues. J Pathol 1996;180: 65-70.
28. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
29. Santini D, Ceccarelli C, Mazzoleni G, et al. Demonstration of cytokeratin intermediate filaments in oocytes of the developing and adult human ovary. Histochemistry 1993;99: 311-19.
30. Lee WH, Shew JY, Hong FD, et al. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotem associated with DNA binding activity. Nature 1988;329:642-5.
31. Faccioli S, Chieco P, Gramantieri L, et al. Cytometric measurement of cell proliferation in echo-guided biopsies from focal lesions of the liver. Mod Pathol 1996;9:120-5.
32. Caulet S, Lesty C, Raphael M, et al. Quantitative study of Ki-67 antibody staining in non-Hodgkin's lymphoma using image analysis. Anal Quant Cytol Histol 1991;13:279-87.
33. Chieco P, Pagnoni M, Romagnoli E, et al. A rapid and simple staining method using toluidine blue for analysing mitotic figures in tissue sections. Histochem J 1993;25:569-77.
34. Snedecor GW, Cochran WG. Statistical methods. Ames, Iowa: The Iowa State University Press, 1990.
35. Hill C. Valeur pronostique d'une variable continue et point de césure optimal. Bull Cancer 1993;80:649-52.
36. Bernstein IH, Garbin CP, Teng GK. Multiple regression and correlation part 2. Advanced applications. In: Bernstein IH, ed. Applied multivariate analysis . New York: Springer Verlag, 1988;123-4.
37. Ceccarelli C, Santini D, Chieco P, et al. Multiple expression patterns of biopathological markers in primary invasive breast carcinoma: a useful tool for elucidating its biological behaviour. Ann Oncol 1995;6:275-82.
38. Fung YK, T'Ang A. The role of retinoblastoma gene in breast cancer development. In: Dickson RB, Lippman MH, eds. Genes, oncogenes, and harmones: advances in cellular and molecular biology of breast cancer. Boston: Kluwer, 1992:59-68.
39. Nieslen NH, Emdin SO, Cajander J, et al. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 1997;14: 295-304.
40. Ping Dou Q. Putative roles of retinoblastoma protein in apoptosis. Apoptosis 1997;2:5-18.
41. Cordon-Cardo C, Richon VM. Expression of the retinoblastoma protein is regulated in normal human tissues. Am J Pathol 1994;144:500-10.
42. Fox SB, Harris AL. The epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia 1997;2: 131-41.
43. De Potter CR. The neu-oncogene: more than a prognostic indicator? Hum Pathol 1994;25:1264-8.
44. Bacus SS, Zelnick CR, Plowman G, et al. Am J Clin Pathol 1994;102(suppl 1):S13-24.
45. Santini D, Ceccarelli C, Taffurelli M, et al. Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J Pathol 1996;179;386-91.
46. Hendrix MJC, Seftor EA, Seftor REB, et al. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 1997;150:483-95.
47. Missero C, Dotto GP. p21waf1/cip1 and terminal differentiation control of normal epithelia. Mol Cell Diff 1996;4:1 16.